FDA approves expanded indication for Lilly’s Jaypirca
RegulatoryapprovedJaypircaPositive
AI Analysis
Summary
The FDA approved an expanded indication for Eli Lilly's Jaypirca as a first-line treatment for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without 17p deletion.
Outcome Details
FDA approved expanded indication for first-line treatment of CLL/SLL
Importance:8/10
Sentiment:
0.90
FDA approvalindication expansiononcologyhematology
Related Companies
Read the original article
Published by Pharmaceutical Technology on October 5, 2026 9:49 AM